Smaller acquisitions and disciplined pricing are proving to be big benefits to a wider number of companies ...

The threat of new tariffs on drugmakers has set off a debate within the biotech industry over whether to cut voluntary ...

Astellas will close a stem cell therapy site. GSK is pushing a Hansoh Pharma-partnered ADC into multiple phase 3 trials. | ...

Brand Institute today announced that the European Medicines Agency (EMA) has approved a pharmaceutical product brand name developed using its proprietary AI-powered name generation platform, Brandi.

Companies have long lamented Europe's fragmented capital markets, single-market adoption on pricing and clinical trials, and ...

Gilead to Buy Ouro Medicines for $2.2 Billion. Why the Deal Is Key to Future Stock Gains. Gilead plans to develop Ouro’s lead drug candidate, gamgertamig, alongside a Belgian pharma company. Nvidia ...

In this week’s edition of InnovationRx, we look at the first robotic cataract surgeries in humans, the underbelly of ...

China’s biotechs are faster and have lower costs, and its drug research threatens to soon overtake the West’s ...

When MEI Pharma announced it was considering its “strategic alternatives” in the wake of a failed merger last year, the options seemed pretty mundane. But, rather than winding down the company as the ...

The third quarter was a pivotal period for both the biotech and pharmaceutical sectors, with regulatory developments and an increase in business deals shaping the landscape for the industries. Public ...

The global pharmaceutical industry has contended with many supply challenges in recent years, from the COVID-19 pandemic to ...

Welcome to Fierce Biotech’s fifth annual layoff tracker, a resource designed to keep pace with the sector’s steady stream of workforce reductions. In 2025, industry layoffs continued to rise year over ...